Saniona Announces Oral Presentation of Tesomet Data in Hypothalamic Obesity at ENDO 2021
March 15, 2021
Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced that data from its Phase 2 clinical trial of Tesomet for hypothalamic obesity (HO) will be presented at the Endocrine Society’s 2021 Annual Meeting (ENDO 2021), which is being held virtually March 20-23, 2021.
ENDO is the leading meeting for endocrinology research and clinical care worldwide. Saniona’s Tesomet data will be featured in a live oral presentation titled, “Weight Loss, Improved Body Composition and Fat Distribution by Tesomet in Acquired Hypothalamic Obesity,” presented by Professor Ulla Feldt-Rasmussen, M.D., DMSc., Department of Medical Endocrinology and Metabolism, Rigshospitalet Copenhagen University Hospital, and Principal Investigator on the Phase 2 study. The presentation will be given on March 23 at 2:15 pm EDT as part of session OR02: What’s New in Weight Management Through the Lifespan? The data are embargoed until the time of presentation.
“We are thrilled to have Dr. Feldt-Rasmussen share the data from our positive Phase 2 trial of Tesomet for the treatment of hypothalamic obesity with the medical community through an oral presentation at such a prestigious medical conference as ENDO,” said Rudolf Baumgartner, M.D., Chief Medical Officer and Head of Clinical Development at Saniona. “There is currently no medicine approved for hypothalamic obesity, a rare disease characterized by intractable weight gain and complicated by uncontrollable hunger. Saniona is committed to pioneering the clinical path forward and addressing this significant unmet need.”
For more information, please contact
Trista Morrison, Chief Communications Officer, Saniona. Office: + 1 (781) 810-9227. Email: email@example.com
The information was submitted for publication, through the agency of the contact person set out above, at 13:00 CET on 15 March 2021.
Saniona is a biopharmaceutical company focused on discovering, developing, and delivering innovative treatments for rare disease patients around the world. The company’s lead product candidate, Tesomet, is in mid-stage clinical trials for the rare diseases Prader-Willi syndrome and hypothalamic obesity. Saniona also has a broad pipeline derived from its proprietary ion channel discovery platform, with lead candidate SAN711 entering Phase 1 studies for rare neuropathic disorders. Saniona intends to develop and commercialize its rare disease products internally. The company has out-licensed other programs, which may provide future supplemental revenue. Saniona is based in Copenhagen, Denmark and Boston, Mass., U.S. The company’s shares are listed on Nasdaq Stockholm Small Cap (OMX: SANION). Read more at www.saniona.com.
Tesomet is an investigational fixed-dose combination therapy of tesofensine (a triple monoamine reuptake inhibitor) and metoprolol (a beta-1 selective blocker). Saniona is advancing Tesomet for hypothalamic obesity and Prader-Willi syndrome, two severe rare disorders characterized by obesity and loss of appetite control. The programs are currently in clinical development. Saniona holds worldwide rights to Tesomet and is actively evaluating opportunities to advance this treatment globally.
About Hypothalamic Obesity (HO)
Hypothalamic obesity (HO) is a rare disorder caused by injury to the hypothalamus, most commonly sustained during surgery to remove a rare, noncancerous tumor called a craniopharyngioma (CP). HO is characterized by rapid, excessive and intractable weight gain that persists despite limited food intake. Patients may have hyperphagia, an uncontrollable hunger, and may display abnormal food seeking behaviors such as stealing food. Additional symptoms may include memory impairment, attention deficit, excessive daytime sleepiness and lethargy, issues with impulse control, depression, and suicide. HO patients are also at increased risk of developing obesity-related comorbid conditions such as type 2 diabetes, non-alcoholic fatty liver disease, hypertension, stroke, and congestive heart failure. Ultimately CP survivors with hypothalamic injury report at least three times higher 20-year mortality than CP survivors without hypothalamic injury. There are no medications approved specifically for HO, and there is no cure for this disease. Many HO patients are treated with approaches used for general obesity such as surgery, medication and lifestyle counseling, but these are often ineffective. The prevalence of HO is estimated to be between 10,000 and 25,000 in the U.S. and between 16,000 and 40,000 in Europe. It occurs most often in children and older adults, creating a burden for both patients and families.
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
Sampo plc: Disclosure Under Chapter 9 Section 5 of the Securities Market Act (BlackRock, Inc.)20.4.2021 15:35:00 CEST | Press release
SAMPO PLC STOCK EXCHANGE RELEASE 20 April 2021 at 4:35 pm Disclosure Under Chapter 9 Section 5 of the Securities Market Act (BlackRock, Inc.) Sampo plc (business code 0142213-3) has received a disclosure under Chapter 9, Section 5 of the Securities Markets Act, according to which the number of Sampo A shares (ISIN: FI009003305) owned directly or indirectly by BlackRock, Inc. (USA tax ID 32-0174421) and its funds increased on 19 April 2021 above five (5) per cent of Sampo plc's total stock. Sampo's share capital comprises 555,351,850 shares, of which 554,151,850 are A shares and 1,200,000 are B shares. Each A share entitles its holder to one (1) vote and each B share to five (5) votes. Thus, the total number of votes is 560,151,850. Total positions of BlackRock, Inc and its funds subject to the notification: % of shares and voting rights (total of A)% of shares and voting rights through financial instruments (total of B)Total of both in % (A+B)Resulting situation on the date on which th
REC Silicon - Notice of Annual General Meeting20.4.2021 15:12:01 CEST | Press release
This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act Lysaker, Norway - April 20, 2021: Notice is hereby given that the Annual General Meeting of REC Silicon ASA (REC) will be held at the offices of Schjødt, Ruseløkkveien 14, Oslo, Norway on May 11, 2021 at 4.00 pm CET. Please find attached Notice of the General Meeting and the Recommendation of the Nomination Committee. All documents are available at https://www.recsilicon.com/investors/agm/ Due to the extraordinary situation with Covid-19, and in light of prevailing travel and meeting recommendations and restrictions, the Board urges shareholders to vote through submission of proxy forms prior to the meeting and not attend the meeting in person. For further information, please contact: James A. May II, Chief Financial Officer Phone: +1 509 989 1023 Email: firstname.lastname@example.org Nils O. Kjerstad, IR Contact Phone: +47 9135 6659 Email: email@example.com About REC
Årsredovisning 2020 är nu publicerad20.4.2021 15:00:00 CEST | Pressemelding
2021-04-20 PRESSRELEASE Årsredovisning 2020är nu publicerad Arcoma publicerar idag sin årsredovisning för verksamhetsåret 2020 på bolagets hemsida www.arcoma.se/about-us/investors. Om Arcoma Arcoma, med lång erfarenhet av branschen, är en ledande leverantör av integrerade digitala röntgensystem med hög kvalitet och avancerad teknik. Arcomas produkter erbjuder den senaste digitala bildtekniken kombinerat med tekniskt avancerade rörliga positioneringssystem, vilket tillsammans med ergonomisk skandinavisk design, erbjuder kunden kompletta, konfigurerbara och funktionella digitala röntgensystem. Bolagets produkter säljs via återförsäljare samt via OEM-kunder och det finns idag över 3 500 av Arcomas röntgensystem installerade i hela världen. Arcoma är listat på Nasdaq First North. Certified Adviser är Erik Penser Bank (tel: 08-4638300, e-mail: firstname.lastname@example.org) För mer information om bolaget besök www.arcoma.se För ytterligare information, vänligen kontakta: Arcomas VD Sanna Rydbe
Skyharbour’s Partner Company Valor Completes Airborne Survey at Hook Lake Uranium Project, Saskatchewan20.4.2021 14:00:00 CEST | Press release
VANCOUVER, British Columbia, April 20, 2021 (GLOBE NEWSWIRE) -- Skyharbour Resources Ltd. (TSX-V: SYH) (OTCQB: SYHBF) (Frankfurt: SC1P) (the “Company”) is pleased to announce that partner company Valor Resources Limited (“Valor”) entered into a contract with Precision GeoSurveys Inc. through TerraLogic Exploration Inc. (“TerraLogic”), the Company’s geological consultants, to undertake a detailed airborne survey over the Hook Lake Project (previously North Falcon Point). The survey commenced in early April 2021 and is now complete. TerraLogic designed the low-level airborne magnetic and VLF-EM survey to cover the entire Hook Lake claim area, using a fixed-wing aircraft, at 75m line-spacing totaling 5,100 line-km. Final data processing, data interpretation, target selection and recommendations for follow-up ground-based exploration and drilling programs will also be handled by TerraLogic. This process is expected to take approximately six weeks, followed immediately by the recommended fi
Acarix publicerar årsredovisningen för 202020.4.2021 13:00:00 CEST | Pressemelding
Pressmeddelande Malmö, 20 april 2021 Acarix publicerar årsredovisningen för 2020 Idag, tisdagen den 20 april, publicerar Acarix sin årsredovisning för verksamhetsåret 2020 på bolagets hemsida www.acarix.com. Årsredovisningen finns även bifogad i pressreleasen. För mer information, vänligen kontakta: Per Persson, vd, e-mail: email@example.com, telefon: +46 73 600 59 90 Informationen lämnades, genom ovanstående kontaktpersons försorg, för offentliggörande vid den tidpunkt som anges av företagets nyhetsdistributör, GlobeNewswire. Om Acarix Acarix grundades 2009 och är noterat på Nasdaq First North Premier Growth Market (ticker: ACARIX). Acarix CADScor®System använder en avancerad sensor som placeras på huden ovanför hjärtat för att lyssna på ljudet av hjärtkontraktion och turbulent flöde. Det har utformats för att vara ett allt-i-ett-system i den meningen att signalen från hjärtat spelas in, bearbetas och visas som en patientspecifik s k CAD-score på skärmen. Presentation av mätresul
Acarix publishes the annual report for 202020.4.2021 13:00:00 CEST | Press release
Press release Malmö, Sweden, April 20, 2021 Acarix publishes the annual report for 2020 Today, Tuesday April 20, Acarix is publishing its Annual Report for 2020 on the company website www.acarix.com. The Annual Report is also attached to this press release. For further information, please contact: Per Persson, CEO, E-mail: firstname.lastname@example.org, Phone: +46 73 600 59 90 The information was provided, through the agency of the above contact person, for publication at the time specified by the company's news distributor, GlobeNewswire. About Acarix: Acarix was established in 2009 and is listed on Nasdaq First North Premier Growth Market (ticker: ACARIX). Acarix’s CADScor®System uses an advanced sensor placed on the skin above the heart to listen to the sounds of cardiac contraction movement and turbulent flow. It has been designed to be an all-in-one system in the sense that the heart signal will be recorded, processed, and displayed as a patient specific score, the CAD-score, on the devi
GW Pharmaceuticals receives European Commission approval for EPIDYOLEX® (cannabidiol) for the treatment of seizures associated with tuberous sclerosis complex20.4.2021 12:30:00 CEST | Press release
– Tuberous sclerosis complex (TSC) represents a third indication for GW’s cannabidiol in Europe – – TSC causes epilepsy in up to 85% of patients, and up to 60% of those patients do not respond to standard anti-epileptic medicines1,2,3– LONDON, April 20, 2021 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq: GWPH) (“GW”, “the Company” or “the Group”), a world leader in discovering, developing and delivering regulatory approved cannabis-based medicines, today announces that the European Commission (EC) has approved the Type II variation application for EPIDYOLEX® (cannabidiol) as an adjunctive treatment of seizures associated with TSC, for patients two years of age and older. This approval, which represents the third indication for GW’s cannabidiol in Europe, paves the way for the expanded launch of the medicine across Europe. “This is an exciting moment for patients, and their families, who are affected by this debilitating disease and may benefit from this treatment. This approval is